Skip to main content
Top
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?

Authors: Menghan Zhu, Nan Jia, Feifei Huang, Xiaoxia Liu, Yuqing Zhao, Xiang Tao, Wei Jiang, Qin Li, Weiwei Feng

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC).

Methods

Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter ≥ 2 cm and 818 low-risk patients with grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter < 2 cm were enrolled in this study. The rate and risk factors of node metastasis were evaluated and compared between the two risk groups. Survival data were analyzed in patients with intermediate-risk EEC with or without lymphadenectomy.

Results

In all, 624 of 1009 (61.8%) patients with intermediate-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 1.9% (12/624), whereas 394 of 818 (48.2%) patients with low-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 0.3% (1/394) (p = 0.021). Notably, intermediate-risk EEC patients with a microcystic, elongated and fragmented (MELF) pattern of invasion, lymphatic vascular space invasion (LVSI), diffuse lesions, or lesions located in the cornua were more likely to have node metastasis. The 5-year overall cancer-related survival and the recurrence-free survival rates of the 742 intermediate-risk EEC patients who were followed for more than 3 years were 99.4% and 94.7%, respectively. In intermediate-risk group, 6 patients (6/443, 1.4%) with lymphadenectomy and 9 patients (9/299, 3.0%) without lymphadenectomy recurred, with a mean recurrence time of 38.3 and 18.7 months respectively. The five-year overall and recurrence-free survival rates of intermediate-risk patients with and without lymphadenectomy were similar (100% vs 98.9%, p = 0.351; 95.2% vs 93.3%, p = 0.464).

Conclusion

Patients with intermediate-risk EEC have low nodal metastasis rate and a favorable outcome whether lymphadenectomy is performed or not. Omission of lymphadenectomy may be a reasonable option in the surgical management of patients with intermediate-risk EEC.
Literature
1.
go back to reference Leijon T, Rosenberg P, Boeryd B. Total abdominal hysterectomy and bilateral salpingo-oophorectomy: a sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Cancer. 1997;7:376–80.CrossRef Leijon T, Rosenberg P, Boeryd B. Total abdominal hysterectomy and bilateral salpingo-oophorectomy: a sufficient treatment for patients with low risk endometrial carcinoma. Int J Gynecol Cancer. 1997;7:376–80.CrossRef
2.
go back to reference Lurain JR. Uterine cancer. In: Berek JS, editor. Berek's & Novak's gynecology. 14th ed: Lipincott Williams & Wilkins; 2007. p. 1343–401. Lurain JR. Uterine cancer. In: Berek JS, editor. Berek's & Novak's gynecology. 14th ed: Lipincott Williams & Wilkins; 2007. p. 1343–401.
3.
go back to reference Coronado PJ, Fasero M, Baquedano L, Martinez-Maestre MA, Casado A, Vidart JA, et al. Impact of the lymphadenectomy in high-risk histologic types of endometrial cancer: a matched-pair study. Int J Gynecol Cancer. 2014;24:703–12.CrossRefPubMed Coronado PJ, Fasero M, Baquedano L, Martinez-Maestre MA, Casado A, Vidart JA, et al. Impact of the lymphadenectomy in high-risk histologic types of endometrial cancer: a matched-pair study. Int J Gynecol Cancer. 2014;24:703–12.CrossRefPubMed
5.
go back to reference Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18:269–73.CrossRefPubMed Chi DS, Barakat RR, Palayekar MJ, Levine DA, Sonoda Y, Alektiar K, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer. 2008;18:269–73.CrossRefPubMed
6.
go back to reference Case AS, Rocconi RP, Straughn JM, Conner M, Novak L, Wang WQ, et al. A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol. 2006;108:1375–9.CrossRefPubMed Case AS, Rocconi RP, Straughn JM, Conner M, Novak L, Wang WQ, et al. A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer. Obstet Gynecol. 2006;108:1375–9.CrossRefPubMed
7.
go back to reference Panici PB, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no nymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRef Panici PB, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no nymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Natl Cancer Inst. 2008;100:1707–16.CrossRef
8.
go back to reference Creutzberg CL, van Putten W, Koper P, Lybeert M, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11.CrossRefPubMed Creutzberg CL, van Putten W, Koper P, Lybeert M, Jobsen JJ, Warlam-Rodenhuis CC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. Lancet. 2000;355:1404–11.CrossRefPubMed
9.
go back to reference Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60(Suppl 8):2035–41.CrossRefPubMed Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. A gynecologic oncology group study. Cancer. 1987;60(Suppl 8):2035–41.CrossRefPubMed
10.
go back to reference Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182:1506–16.CrossRefPubMed Mariani A, Webb MJ, Keeney GL, Haddock MG, Calori G, Podratz KC. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol. 2000;182:1506–16.CrossRefPubMed
11.
go back to reference Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.CrossRefPubMed Todo Y, Kato H, Kaneuchi M, Watari H, Takeda M, Sakuragi N. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet. 2010;375:1165–72.CrossRefPubMed
13.
go back to reference Doll KM, Tseng J, Denslow SA, Fader AN, Gehrig PA. High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol. 2014;132:44–9.CrossRefPubMed Doll KM, Tseng J, Denslow SA, Fader AN, Gehrig PA. High-grade endometrial cancer: revisiting the impact of tumor size and location on outcomes. Gynecol Oncol. 2014;132:44–9.CrossRefPubMed
14.
go back to reference Zhang CY, Wang C, Feng WW. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer. 2012;22:1373–7.CrossRefPubMed Zhang CY, Wang C, Feng WW. Clinicopathological risk factors for pelvic lymph node metastasis in clinical early-stage endometrioid endometrial adenocarcinoma. Int J Gynecol Cancer. 2012;22:1373–7.CrossRefPubMed
15.
go back to reference Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2–30.CrossRefPubMed Colombo N, Creutzberg C, Amant F, Bosse T, Gonzalez-Martin A, Ledermann J, et al. ESMO-ESGO-ESTRO consensus conference on endometrial cancer diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26:2–30.CrossRefPubMed
16.
go back to reference Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2015;131(Suppl 2):S96–104.CrossRefPubMed Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. Int J Gynaecol Obstet. 2015;131(Suppl 2):S96–104.CrossRefPubMed
17.
go back to reference Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012;119:286–92.CrossRefPubMedPubMedCentral Milam MR, Java J, Walker JL, Metzinger DS, Parker LP, Coleman RL. Nodal metastasis risk in endometrioid endometrial cancer. Obstet Gynecol. 2012;119:286–92.CrossRefPubMedPubMedCentral
18.
go back to reference Dowdy SC, Borah BJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Haas LR, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012;127:5–10.CrossRefPubMed Dowdy SC, Borah BJ, Bakkum-Gamez JN, Weaver AL, McGree ME, Haas LR, et al. Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol. 2012;127:5–10.CrossRefPubMed
19.
go back to reference Dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer. 2015;25:1292–9.CrossRefPubMedPubMedCentral Dos Reis R, Burzawa JK, Tsunoda AT, Hosaka M, Frumovitz M, Westin SN, et al. Lymphovascular space invasion portends poor prognosis in low-risk endometrial cancer. Int J Gynecol Cancer. 2015;25:1292–9.CrossRefPubMedPubMedCentral
20.
go back to reference AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294–9.CrossRefPubMed AlHilli MM, Podratz KC, Dowdy SC, Bakkum-Gamez JN, Weaver AL, McGree ME, et al. Preoperative biopsy and intraoperative tumor diameter predict lymph node dissemination in endometrial cancer. Gynecol Oncol. 2013;128:294–9.CrossRefPubMed
21.
go back to reference Canlorbe G, Bendifallah S, Laas E, Raimond E, Graesslin O, Hudry D, et al. Tumor size, an additional prognostic factor to include in low-risk endometrial cancer: results of a French multicenter study. Ann Surg Oncol. 2016;23:171–7.CrossRefPubMed Canlorbe G, Bendifallah S, Laas E, Raimond E, Graesslin O, Hudry D, et al. Tumor size, an additional prognostic factor to include in low-risk endometrial cancer: results of a French multicenter study. Ann Surg Oncol. 2016;23:171–7.CrossRefPubMed
22.
go back to reference Turan T, Hizli D, Sarici S, Boran N, Gundogdu B, Karadag B, et al. Is it possible to predict para-aortic lymph node metastasis in endometrial cancer? Eur J Obstet Gynecol Reprod Biol. 2011;158:274–9.CrossRefPubMed Turan T, Hizli D, Sarici S, Boran N, Gundogdu B, Karadag B, et al. Is it possible to predict para-aortic lymph node metastasis in endometrial cancer? Eur J Obstet Gynecol Reprod Biol. 2011;158:274–9.CrossRefPubMed
23.
go back to reference Borghesi Y, Narducci F, Bresson L, Tresch E, Meurant JP, Cousin S, et al. Managing endometrial cancer: the role of pelvic lymphadenectomy and secondary surgery. Ann Surg Oncol. 2015;22(Suppl 3):S936–43.CrossRefPubMed Borghesi Y, Narducci F, Bresson L, Tresch E, Meurant JP, Cousin S, et al. Managing endometrial cancer: the role of pelvic lymphadenectomy and secondary surgery. Ann Surg Oncol. 2015;22(Suppl 3):S936–43.CrossRefPubMed
24.
go back to reference Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, et al. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol. 2013;37:1728–36.CrossRefPubMedPubMedCentral Euscher E, Fox P, Bassett R, Al-Ghawi H, Ali-Fehmi R, Barbuto D, et al. The pattern of myometrial invasion as a predictor of lymph node metastasis or extrauterine disease in low-grade endometrial carcinoma. Am J Surg Pathol. 2013;37:1728–36.CrossRefPubMedPubMedCentral
25.
go back to reference Briet JM, Hollema H, Reesink N, Aalders JG, Mourits M, Ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799–804.CrossRefPubMed Briet JM, Hollema H, Reesink N, Aalders JG, Mourits M, Ten Hoor KA, et al. Lymphvascular space involvement: an independent prognostic factor in endometrial cancer. Gynecol Oncol. 2005;96:799–804.CrossRefPubMed
26.
go back to reference Han GM, Lim D, Leitao MM, Abu-Rustum NR, Soslow RA. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology. 2014;64:389–98.CrossRefPubMed Han GM, Lim D, Leitao MM, Abu-Rustum NR, Soslow RA. Histological features associated with occult lymph node metastasis in FIGO clinical stage I, grade I endometrioid carcinoma. Histopathology. 2014;64:389–98.CrossRefPubMed
27.
go back to reference Bell JG, Minnick A, Reid GC, Judis J, Brownell M. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol. 1997;66:388–92.CrossRefPubMed Bell JG, Minnick A, Reid GC, Judis J, Brownell M. Relationship of nonstaging pathological risk factors to lymph node metastasis and recurrence in clinical stage I endometrial carcinoma. Gynecol Oncol. 1997;66:388–92.CrossRefPubMed
28.
go back to reference Hertel JD, Huettner PC, Pfeifer JD. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol. 2014;33:127–34.CrossRefPubMed Hertel JD, Huettner PC, Pfeifer JD. Lymphovascular space invasion in microcystic elongated and fragmented (MELF)-pattern well-differentiated endometrioid adenocarcinoma is associated with a higher rate of lymph node metastasis. Int J Gynecol Pathol. 2014;33:127–34.CrossRefPubMed
29.
go back to reference Pavlakis K, Messini I, Vrekoussis T, Panoskaltsis T, Chrysanthakis D, Yiannou P, et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology. 2011;58:966–73.CrossRefPubMed Pavlakis K, Messini I, Vrekoussis T, Panoskaltsis T, Chrysanthakis D, Yiannou P, et al. MELF invasion in endometrial cancer as a risk factor for lymph node metastasis. Histopathology. 2011;58:966–73.CrossRefPubMed
30.
go back to reference Stewart C, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology. 2009;41:454–9.CrossRefPubMed Stewart C, Brennan BA, Leung YC, Little L. MELF pattern invasion in endometrial carcinoma: association with low grade, myoinvasive endometrioid tumours, focal mucinous differentiation and vascular invasion. Pathology. 2009;41:454–9.CrossRefPubMed
31.
go back to reference DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol. 1985;151:1009–15.CrossRefPubMed DiSaia PJ, Creasman WT, Boronow RC, Blessing JA. Risk factors and recurrent patterns in stage I endometrial cancer. Am J Obstet Gynecol. 1985;151:1009–15.CrossRefPubMed
32.
go back to reference Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol. 1991;40:55–65.CrossRefPubMed Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a gynecologic oncology group study. Gynecol Oncol. 1991;40:55–65.CrossRefPubMed
Metadata
Title
Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
Authors
Menghan Zhu
Nan Jia
Feifei Huang
Xiaoxia Liu
Yuqing Zhao
Xiang Tao
Wei Jiang
Qin Li
Weiwei Feng
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3671-0

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine